人福医药集团股份公司关于注射用米卡芬净钠获得美国FDA批准文号的公告

Core Viewpoint - The company has received FDA approval for Micafungin for Injection, marking a significant step in expanding its presence in the U.S. generic drug market [1][2]. Group 1: FDA Approval Details - The FDA has granted approval for Micafungin for Injection under ANDA number 219518, available in 50 mg and 100 mg vials [1]. - The drug is indicated for the treatment of candidemia, acute disseminated candidiasis, candidal peritonitis, and abscesses in adults and pediatric patients aged 4 months and older, as well as for the prevention of candidal infections in hematopoietic stem cell transplant recipients [1]. Group 2: Market Potential and Financials - The total R&D investment for Micafungin has been approximately RMB 6.8 million, with projected annual sales in the U.S. market estimated at around $67 million for 2024 [2]. - Major competitors in the U.S. market include FRESENIUS and SAGENT PHARMACEUTICALS [2]. Group 3: Future Plans - The company plans to actively advance the market launch preparations for Micafungin in the U.S. following the FDA approval [2].